EyE on U | Richard Trembath: Medtech joint lab brings together GBA edges and KCL expertise

The human body is like an ultra-high-precision computer, and every part is interlocked. Modern medicine has been trying to conquer the "high mountain" of the gene, but in the face of intractable diseases and biological sciences of unimaginable complexity, there is still a long way ahead.

The "Hong Kong Innovation and Technology Development Blueprint" recommends that the government focus on promoting the development of the life and health technology industry. As a two-way platform for the nation, the Hong Kong Institute of Science & Innovation (HKISI), CAS, cooperates with King's College London (KCL), which is quite prestigious in the medical field, to establish a joint laboratory, to contribute to Hong Kong's medical research.

In this episode, we're glad to invite Professor Richard Trembath, the Senior Vice President for Health & Life Sciences of KCL, who has experience in in-depth research in the identification of disease-causing genes and the treatment of special diseases, to talk about issues concerning human health and cutting-edge medical technology.

"In the area of AI, HK has some really remarkable strengths, which, of course, also reflect on the position globally that HK presents here in the wider China arena," he said.

What are KCL's strengths in the field of medtech? Why HK was chosen as the base of the joint laboratory? What are the current treatments for diseases caused by genetic defects? Watch the video now for more details.